PXMD(Delisted)
PaxMedicaยทNASDAQ
--
--(--)
PXMD Profile
Paxmedica, Inc.
A clinical stage biopharmaceutical company that develops novel anti-purinergic drug therapies for the treatment of disorders with intractable neurologic symptoms
303 South Broadway, Suite 125, Tarrytown, NY 10591
--
PaxMedica, Inc., was incorporated as a Delaware limited liability company on April 5, 2018 and converted to a Delaware corporation on April 15, 2020. The Company is an early clinical-stage biopharmaceutical company focused on the development of antipurinergic therapies (or APT) for the treatment of neurodevelopmental disorders, including autism spectrum disorder (ASD) and brittle X syndrome ataxia (FXTAS).
